Total Funding
81
44
Total FundingSeries D raised
Growth Score 81 in past quarter
0 pts
Heat Score 44 in past quarter
8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
4521
Pathos is a biotechnology company that leverages AI to accelerate oncology drug development.
- Iker Huerga: Chief Executive OfficerPast Role: Da'at Technologies, Co-Founder and CTO
- Ryan Fukushima: CofounderPast Role: Hyde Park Venture Partners, Senior Associate
About the Company
Pathos is at the forefront of a novel approach to AI-driven drug development. This approach harnesses multimodal data, cutting-edge Artificial Intelligence, and profound clinical understanding to expedite the introduction of new therapies for patients. With an emphasis on Artificial Intelligence, clinical development, and implementation, Pathos is
dedicated to enhancing patient outcomes by speeding up the transition from molecule to medicine.
